These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34312502)

  • 1. Publisher Correction: Questions swirl around failures of disease-modifying Huntington's drugs.
    Sheridan C
    Nat Biotechnol; 2021 Aug; 39(8):1017. PubMed ID: 34312502
    [No Abstract]   [Full Text] [Related]  

  • 2. Publisher Correction: Questions swirl around failures of disease-modifying Huntington's drugs.
    Sheridan C
    Nat Biotechnol; 2021 Jul; 39(7):893. PubMed ID: 34155408
    [No Abstract]   [Full Text] [Related]  

  • 3. Investigational agents for the management of Huntington's disease.
    Müller T
    Expert Opin Investig Drugs; 2017 Feb; 26(2):175-185. PubMed ID: 27927041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs.
    Simpson JA; Lovecky D; Kogan J; Vetter LA; Yohrling GJ
    J Huntingtons Dis; 2016 Dec; 5(4):395-403. PubMed ID: 27983566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
    Feigin A; Evans EE; Fisher TL; Leonard JE; Smith ES; Reader A; Mishra V; Manber R; Walters KA; Kowarski L; Oakes D; Siemers E; Kieburtz KD; Zauderer M;
    Nat Med; 2024 Feb; 30(2):606. PubMed ID: 36195687
    [No Abstract]   [Full Text] [Related]  

  • 6. Disease-Modification in Huntington's Disease: Moving Away from a Single-Target Approach.
    Jensen MP; Barker RA
    J Huntingtons Dis; 2019; 8(1):9-22. PubMed ID: 30636742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Publisher Correction: Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease.
    Aron R; Pellegrini P; Green EW; Maddison DC; Opoku-Nsiah K; Oliveira AO; Wong JS; Daub AC; Giorgini F; Muchowski P; Finkbeiner S
    Nat Commun; 2020 May; 11(1):2374. PubMed ID: 32382035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Publisher Correction: Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease.
    Aron R; Pellegrini P; Green EW; Maddison DC; Opoku-Nsiah K; Wong JS; Daub AC; Giorgini F; Finkbeiner S
    Nat Commun; 2018 Oct; 9(1):4333. PubMed ID: 30323191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational drugs for the management of Huntington's disease: are we there yet?
    Kulkarni P; Saxena U
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1595-603. PubMed ID: 25084527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does tissue transglutaminase play a role in Huntington's disease?
    Lesort M; Chun W; Tucholski J; Johnson GV
    Neurochem Int; 2002 Jan; 40(1):37-52. PubMed ID: 11738471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.
    Vinther-Jensen T; Simonsen AH; Budtz-Jørgensen E; Hjermind LE; Nielsen JE
    Eur J Neurol; 2015 Oct; 22(10):1378-84. PubMed ID: 26073975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension, Antihypertensive Use and the Delayed-Onset of Huntington's Disease.
    Steventon JJ; Rosser AE; Hart E; Murphy K
    Mov Disord; 2020 Jun; 35(6):937-946. PubMed ID: 32017180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huntington's disease.
    Ha AD; Fung VS
    Curr Opin Neurol; 2012 Aug; 25(4):491-8. PubMed ID: 22772878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease.
    Hsu YT; Chang YG; Chang CP; Siew JJ; Chen HM; Tsai CH; Chern Y
    Mov Disord; 2017 Nov; 32(11):1600-1609. PubMed ID: 28782830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut dysbiosis in Huntington's disease: associations among gut microbiota, cognitive performance and clinical outcomes.
    Wasser CI; Mercieca EC; Kong G; Hannan AJ; McKeown SJ; Glikmann-Johnston Y; Stout JC
    Brain Commun; 2020; 2(2):fcaa110. PubMed ID: 33005892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntington's disease: clinical characteristics, pathogenesis and therapies.
    Nakamura K; Aminoff MJ
    Drugs Today (Barc); 2007 Feb; 43(2):97-116. PubMed ID: 17353947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminating chorea-acanthocytosis from Huntington's disease with single-case voxel-based morphometry analysis.
    Suzuki F; Sato N; Ota M; Sugiyama A; Shigemoto Y; Morimoto E; Kimura Y; Wakasugi N; Takahashi Y; Futamura A; Kawamura M; Ono K; Nakamura M; Sano A; Watanabe M; Matsuda H; Abe O
    J Neurol Sci; 2020 Jan; 408():116545. PubMed ID: 31704285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Juvenile Huntington's disease: two case reports and a review of the literature.
    Lesinskienė S; Rojaka D; Praninskienė R; Morkūnienė A; Matulevičienė A; Utkus A
    J Med Case Rep; 2020 Oct; 14(1):173. PubMed ID: 32998776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.
    Huang Q; Zhou D; Sapp E; Aizawa H; Ge P; Bird ED; Vonsattel JP; DiFiglia M
    Neuroscience; 1995 Mar; 65(2):397-407. PubMed ID: 7777157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.